Skip to content
Axcess News – Lifestyle
Author:
Brii Biosciences Limited
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure
November 5, 2026
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
August 20, 2026
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
July 2, 2026
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
May 27, 2026